Surprise strong showing for Galapagos' JAK1 inhibitor in rheumatoid arthritis
This article was originally published in Scrip
Galapagos has reported unexpectedly strong Phase II data with its JAK1 inhibitor GLPG0634 in rheumatoid arthritis (RA). The company has yet to decide whether or not to partner the product, but said its 2011 financial guidance "will only be achievable in the event the GLPG0634 programme is successfully partnered before year end".
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.